Get all the latest news on coronavirus and more delivered daily to your inbox. Sign up here.In the rush to find a viable treatment option for COVID-19 patients, scientists at the University of North Carolina at Chapel Hill hope to have found at least one solution.Researchers at the university’s Gillings School of Global Public Health developed a potential antiviral treatment they claim “shows promise in reducing lung damage” in those infected with the novel virus.POSSIBLE CORONAVIRUS TREATMENT LEAVES LUPUS PATIENTS WITH NEW CHALLENGES: ‘THERE ARE BACKORDERS’The antiviral treatment, EIDD-2801, was tested in mice infected with both MERS-CoV and SARS-CoV-2, the virus that causes COVID-19. The drug was also tested on cultured human lung cells infected with SARS-CoV-2, according to a news release from UNC at Chapel Hill.The researchers found that the antiviral treatment, which can be administered in a pill form, prevented severe lung infection in mice when used as a prophylactic.“When given as a treatment 12 or 24 hours after infection has begun, EIDD-2801 can reduce the degree of lung damage and weight loss in mice,” the news release stated. “This window of opportunity is expected to be longer in humans because the period between coronavirus disease onset and death is generally


Continue To Full Article